Last updated: February 20, 2026
What is NDC 49884-0009?
NDC 49884-0009 is the National Drug Code for Sunosi (solriamfetol), a prescription medication used to treat excessive sleepiness associated with narcolepsy and obstructive sleep apnea (OSA). It was approved by the FDA in June 2021.
Market Overview
Market Landscape
The global sleep disorder market was valued around $3.2 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 8.2% through 2028. The strong drivers include increasing prevalence of sleep disorders, rising awareness, and new therapeutic options.
Key Competitors
- Modafinil (e.g., Provigil): US sales reached approximately $650 million in 2022.
- Armodafinil (e.g., Nuvigil): US sales approximately $440 million in 2022.
- Ozempic (e.g., for opioid-induced sleep disturbances): Smaller niche segment although competing indirectly.
Market Penetration
Sunosi entered a competitive space with established drugs. Early market share estimates suggest sales of roughly $30 million in the first year, with potential to reach $150 million worldwide by 2025, contingent on physician adoption and formulary coverage.
Reimbursement Environment
Medicare Part D covers Sunosi with a tier 2 or 3 formulary position for most insurers. Variable patient copayments are typical, ranging from $10-$50 per prescription. Private insurers' coverage is generally favorable, enabling broader patient access.
Pricing Analysis
Current Price Points
- Average wholesale price (AWP): Approximately $15 per tablet.
- Typical dosing: 75-150 mg daily, equating to $15-$30 per day.
- Monthly cost: $450-$900, depending on dose.
Comparison to Competitors
| Drug |
Price per tablet |
Dose |
Monthly Cost (approx.) |
Market Position |
| Sunosi (49884-0009) |
$15 |
75-150 mg |
$450–$900 |
New entrant; lower priced relative to modafinil |
| Modafinil (Brand) |
$10 |
100–200 mg |
$300–$600 |
Established; generic availability lowers price |
| Armodafinil |
$12 |
150 mg |
$360 |
Slightly more expensive; generic available |
Price Trends and Possible Trajectories
- Initial Period (2023-2024): Prices tend to hold steady due to market entry costs and limited competition.
- Post-Patent Expiration (Expected around 2031): Introduction of generics could reduce per-unit prices by 40-60%, lowering monthly costs to $150-$300.
Factors Influencing Price Projections
- Market penetration: Increased adoption could sustain higher prices temporarily.
- Reimbursement policies: Favorable insurance coverage supports stable pricing.
- Regulatory changes: Future policy adjustments might impact pricing dynamics.
- Generic entry: Typically causes a drop in prices by nearly half within two years of patent expiry.
Future Market and Price Projections
| Year |
Market Size (USD Millions) |
Estimated Price Range |
Competitive Dynamics |
| 2023 |
$30 |
$15 per tablet |
Limited competition, early adoption |
| 2024 |
$60 |
$15–$13 per tablet |
Increasing awareness, early competitors |
| 2025 |
$150 |
$12–$10 per tablet |
Growing market share, possible price pressure |
| 2030+ |
$250–$300 |
$8–$10 per tablet |
Generics entering, price reduction likely |
Risks and Challenges
- Market acceptance: Resistance from established treatment providers could limit growth.
- Pricing pressure: Entry of generics around 2031 may significantly lower prices.
- Regulatory and reimbursement changes: Shifts may impact access and profitability.
Key Takeaways
- NDC 49884-0009 (Sunosi) entered a competitive market with established pharmacotherapies.
- Current US prices are approximately $15 per tablet, translating to $450–$900 monthly.
- Market growth depends on physician adoption, reimbursement, and insurance coverage.
- Price reductions are likely post-patent expiration (expected around 2031) due to generics.
- The overall market is expected to expand at a healthy CAGR, with moderate pricing pressure over time.
FAQs
Q1: What advantages does Sunosi have over existing sleep medications?
A1: Sunosi offers a different mechanism of action (dopamine and norepinephrine reuptake inhibitor), potentially fewer side effects, and a lower abuse potential compared to traditional stimulants.
Q2: How does the pricing of Sunosi compare internationally?
A2: International prices vary; European markets often see lower prices due to formulary negotiations. Exact figures depend on country-specific health policies.
Q3: What factors influence patient access to Sunosi?
A3: Coverage policies, copay assistance programs, physician prescribing habits, and clinician familiarity affect access.
Q4: When is generic competition expected?
A4: Patent protection typically lasts 12-14 years from approval, with generic versions arriving approximately in 2031.
Q5: How might future market trends affect investment decisions?
A: Growing awareness of sleep disorders and new indications could boost sales; however, patent expirations and emerging generics could diminish margins.
References
[1] Global Data. Sleep disorder market report, 2022.
[2] IQVIA. US pharmaceutical sales data, 2022.
[3] US FDA. Drug approvals and patent information, 2021.
